Showing 41 - 60 results of 21,342 for search '(( significant decrease decrease ) OR ( significant gap decrease ))', query time: 0.19s Refine Results
  1. 41

    ECoG timescales decrease during spatial attention. by Isabel Raposo (21615517)

    Published 2025
    “…Bottom: timescales significantly decrease during covert attention relative to the attend-out condition (two locations: <i>p</i> = 0.0244; four locations: <i>p</i> < 0.0001; mean ± SEM; whiskers indicate maximum and minimum; dots correspond to individual electrodes). …”
  2. 42
  3. 43
  4. 44
  5. 45
  6. 46
  7. 47
  8. 48
  9. 49

    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  10. 50

    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  11. 51

    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  12. 52

    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  13. 53

    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  14. 54

    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  15. 55

    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  16. 56

    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  17. 57
  18. 58
  19. 59

    Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index. by Søren Egstrand (10906087)

    Published 2025
    “…All groups were compared by Kruskal Wallis test with <i>post hoc</i> test after Dunn with Bonferroni adjustment showing significant decreased Ki-67 labeling index of <i>Cina1</i> compared to <i>Cina2</i> (p = 0.006) and the untreated CKD groups (p = 0.0001 and p = 0.0002, respectively). …”
  20. 60